Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8158675 | Compounds and methods for the treatment or prevention of infections Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, Y1, and Z are as defined herein, are useful for treating flaviv... | 04/17/2012 |
| 8106091 | Inhibitors of IKK-beta serine-threonine protein kinase Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R7 is hydrogen or optionally substituted (C1 | 01/31/2012 |
| 8063100 | Process for the synthesis of strontium ranelate and its hydrates A process for the industrial synthesis of strontium ranelate of formula (I): and its hydrates. ... | 11/22/2011 |
| 8003685 | Thiophene analogues for the treatment or prevention of flavivirus infections Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections. ... | 08/23/2011 |
| 7981925 | Compounds that modulate intracellular calcium Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with othe... | 07/19/2011 |
| 7745482 | Alpha crystalline form of strontium ranelate Alpha crystalline form of strontium ranelate of formula (I): characterised by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in... | 06/29/2010 |
| 7732484 | Use of selective adenosine Areceptor allosteric enhancers to manipulate angiogenesis Disclosed is the use of selective adenosine A1 allosteric enhancers to induce angiogenesis at a desired location for treating conditions in which increased angiogenesis is desired, such as stroke, heart disease and peripheral vascular disease. ... | 06/08/2010 |
| 7709523 | Alpha-aminoamide derivatives useful as antimigraine agents α-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the p... | 05/04/2010 |
| 7696244 | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof The invention provides compositions, including pharmaceutical preparations, which comprise one or more substituted thiophene, benzofuran, pyrimidinetrione, dihydropyridine, tetrahydrocarbazol or anthraquinone compounds. The invention also features methods of use of ... | 04/13/2010 |
| 7652064 | AMPA receptor potentiators The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation. ... | 01/26/2010 |
| 7572826 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical comp... | 08/11/2009 |
| 7569600 | Compounds and methods for the treatment of prevention of infections Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, Y1, and Z are as defined herein, are useful for treating flaviv... | 08/04/2009 |
| 7423061 | Substitute thiophenes and uses thereof This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. ... | 09/09/2008 |
| 7417057 | Pesticidal heterocycles It has now been found that certain novel heterocyclic derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): R Preferred are those compounds of formula (I) where R2 and R3 taken together is ═NCH(R | 08/26/2008 |
| 7402608 | Compounds and methods for the treatment or prevention of infections Compounds represented by formula: wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in ... | 07/22/2008 |
| 7393868 | AMPA receptor potentiators The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation. ... | 07/01/2008 |
| 7388012 | (Hydrazido)(amino)thiophene compounds Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, ... | 06/17/2008 |
| 7375131 | NF-κB inhibitors The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in ... | 05/20/2008 |
| 7358376 | Substituted Thiophene compounds The invention relates to heteroaromatic carboxamides of formula (I), wherein A, R1, R2 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical c... | 04/15/2008 |
| 7351841 | Heterocyclic compounds and thrombopoietin receptor activators A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C | 04/01/2008 |
| 7329670 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the tre... | 02/12/2008 |
| 7329686 | Substituted thiophene compounds There are provided novel compounds of formula (I) wherein R1, R2, R3, R10, M, Q, T, U, Y, V and W are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their prepara... | 02/12/2008 |
| 7326729 | CXCR1 and CXCR2 chemokine antagonists The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease. ... | 02/05/2008 |
| 7300952 | NF-κb inhibitors The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in ... | 11/27/2007 |
| 7247317 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant | 07/24/2007 |
| 7226991 | Phenylalanine derivatives Disclosed herein are phenylalanine derivative compounds of the following formula W—Y—(AA)n—Z wherein Y is a phenylalanyl radical, AA is an amino acid, n is an integer of 1 to 15, and substituent variables W and Z are as described... | 06/05/2007 |
| 7196114 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use The invention relates to compounds of the formula I where the radicals are as defined, and their physiological... | 03/27/2007 |
| 7196207 | Method for producing 2-alkyl-3-aminothiophene derivative A method for reducing a sulfur-containing compound by hydrogenation using a noble metal catalyst which method is exemplified by an industrial method for producing a 2-alkyl-3-aminothiophene derivative with high economical efficiency by hydrogenating a 2-alkenyl-3-am... | 03/27/2007 |
| 7179836 | Chemical compounds Thiophene derivatives are described herein. The described invention also includes methods of making such thiophene derivatives as well as methods of using the same in the treatment of diseases. ... | 02/20/2007 |
| 7176201 | Modulation of anxiety through blockade of anandamide hydrolysis Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or ... | 02/13/2007 |
| 7166639 | NF-κB inhibitors The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in ... | 01/23/2007 |
| 7138529 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the... | 11/21/2006 |
| 7112607 | Allosteric adenosine receptor modulators The present invention relates to compounds of formula (IA): the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including p... | 09/26/2006 |
| 7105564 | Pharmaceutical composition comprising a dual antagonist against PGD/TXAreceptors having a [2.2.1] or [3.1.1] bicyclic skeleton The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D2 receptor and pharmaceutical compositions comprising them. A compound of the formula (I): | 09/12/2006 |
| 7098240 | Compounds The invention relates to thiophene carboxamides of formula (I), wherein R1, R2, R3, A, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them an... | 08/29/2006 |
| 7084178 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives A series of N-cycloalkylcarboxamide derivatives of N-benzyl benzenesulfonamides of Formula I are described. The compounds inhibit β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's... | 08/01/2006 |
| 7049410 | Antibodies to a novel EGF-receptor related protein (ERRP) This invention relates to ERRP (EGF-Receptor Related Protein) specific antibodies that could be used 1) to study the functional properties of ERRP and; 2) as a diagnostic and prognostic tool for malignancies. Preferably, the antibody reacts with a segment of ERRP co... | 05/23/2006 |
| 7019024 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof. ... | 03/28/2006 |
| 7019027 | 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors The present invention relates to a compound of formula (I): wherein: R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and ... | 03/28/2006 |
| 6992081 | Compounds to treat Alzheimer's disease The present invention is directed toward substituted hydroxyethylene compounds of formulas (XII) (XIII), and (XIV) useful in treating Alzheimer's disease and other similar diseases. ... | 01/31/2006 |
